| REVIEW ARTICLE |
|
| Year : 2017 | Volume
: 1
| Issue : 2 | Page : 84-87 |
|
|
Valbenazine: Drug review
Mahanjit Konwar, Nithya J Gogtay, Urmila M Thatte
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
Correspondence Address:
Mahanjit Konwar
Department of Clinical Pharmacology, Multispeciality Building, Seth GS Medical College and KEM Hospital, Parel, Mumbai - 400 012, Maharashtra
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/aip.aip_41_17
|
|
|
Valbenazine is the first drug approved by the US Food and Drug Administration for the treatment of adults with tardive dyskinesia (TD) on April 11, 2017. It acts as a reversible inhibitor of vesicular monoamine transporter 2. It is available orally with a starting dose of 40 mg once daily which can be increased after 1 week to the recommended dose of 80 mg. Clinical trials showed positive outcomes in Abnormal Involuntary Movement Scale and Clinical Global Impression - Global Improvement of TD score with respect to placebo. Valbenazine has an acceptable safety and tolerability profile, the most common side effect observed is somnolence. However, long-term study is lacking, and more data are required to establish its full benefits and concomitant risks which can be missed in the recent trials.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
